Spots Global Cancer Trial Database for epithelioid mesothelioma
Every month we try and update this database with for epithelioid mesothelioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | NCT01861301 | Epithelioid Mes... Recurrent Malig... Sarcomatoid Mes... Stage II Pleura... Stage III Pleur... Stage IV Pleura... | Laboratory Biom... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab in Treating Patients With Malignant Mesothelioma | NCT02399371 | Biphasic Mesoth... Epithelioid Mes... Peritoneal Mali... Pleural Biphasi... Pleural Epithel... Pleural Maligna... Pleural Sarcoma... Recurrent Perit... Recurrent Pleur... Sarcomatoid Mes... | Pembrolizumab Laboratory Biom... Pharmacogenomic... | 18 Years - | University of Chicago | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | NCT01861301 | Epithelioid Mes... Recurrent Malig... Sarcomatoid Mes... Stage II Pleura... Stage III Pleur... Stage IV Pleura... | Laboratory Biom... Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | NCT03228537 | Biphasic Mesoth... Epithelioid Mes... Stage I Pleural... Stage IA Pleura... Stage IB Pleura... Stage II Pleura... Stage III Pleur... | Atezolizumab Cisplatin Extrapleural Pn... Pemetrexed Diso... Pleurectomy Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma | NCT01064648 | Epithelioid Mes... Pleural Maligna... Recurrent Malig... Sarcomatoid Mes... | Cediranib Malea... Cisplatin Laboratory Biom... Pemetrexed Diso... Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | NCT01861301 | Epithelioid Mes... Recurrent Malig... Sarcomatoid Mes... Stage II Pleura... Stage III Pleur... Stage IV Pleura... | Laboratory Biom... Tivantinib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
